NCT00830648

Safety of a Second Dose of Biken's Varicella Vaccine

Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 122 (actual)
• Sponsor: Sanofi Pasteur, a Sanofi Company · Industry
• Sex: All
• Age: 4 Years – 6 Years
• Healthy volunteers: Accepted

Summary

The objective of the present study is to assess and document the safety of a second dose of Varicella Biken vaccine administered at 4 to 6 years of age in healthy children having previously received a first dose of Varicella Biken vaccine. All subjects will receive a second dose of Varicella vaccine (Varicella Biken) at 4 to 6 years of age. The expected total duration of follow-up (first visit to last visit) for each subject will be one month.

Conditions

• Varicella

Interventions

Type	Name	Description
BIOLOGICAL	Live Attenuated Varicella Virus Vaccine	0.5 mL, Subcutaneous

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-10-01
• Completion: 2009-12-01
• First posted: 2009-01-28
• Last updated: 2013-06-10

Locations

1 site across 1 country: Argentina